Literature DB >> 21443080

Surgery for periductal infiltrating type intrahepatic cholangiocarcinoma without hilar invasion provides a better outcome than for mass-forming type intrahepatic cholangiocarcinoma without hilar invasion.

Kenichiro Imai1, Masaklzazu Yamamoto, Shunichi Ariizumi.   

Abstract

BACKGROUND/AIMS: The objective of this study was to clarify the clinicopathological features and surgical outcomes in patients with periductal infiltrating type intrahepatic cholangiocarcinoma without hilar invasion.
METHODOLOGY: Nine patients with periductal infiltrating (PI) type intrahepatic cholangiocarcinoma (ICC) without hilar invasion underwent curative surgery. The clinicopathological characteristics and surgical outcomes in these patients were compared with those of 49 patients with mass-forming (MF) type ICC without hilar invasion.
RESULTS: None of the patients in this investigation had jaundice. The tumor size for PI type ICC without hilar invasion was smaller than that of the MF type without hilar invasion. The rates of lymph node metastasis and recurrence in the patients with the PI type ICC without hilar invasion were lower than those of the patients with the MF type ICC without hilar invasion. The 5-year survival rates after surgery for the patients with the PI type ICC and the MF type ICC without hilar invasion were 85.7% and 41.2%, respectively (p = 0.032).
CONCLUSIONS: The patients with PI type ICC without hilar invasion therefore tend to have favorable surgical outcomes.

Entities:  

Mesh:

Year:  2010        PMID: 21443080

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

Review 1.  Pathology of intrahepatic cholangiocarcinoma.

Authors:  Sandrine Vijgen; Benoit Terris; Laura Rubbia-Brandt
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

Review 2.  Surgical outcomes of intrahepatic cholangiocarcinoma.

Authors:  Masakazu Yamamoto; Shun-ichi Ariizumi
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

3.  Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

Authors:  Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu Yamamoto
Journal:  Liver Cancer       Date:  2022-02-23       Impact factor: 12.430

4.  Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system.

Authors:  Ze-Wu Meng; Wei Pan; Hai-Jie Hong; Jiang-Zhi Chen; Yan-Ling Chen
Journal:  Oncotarget       Date:  2017-09-15

5.  Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.

Authors:  Xiaohong Pu; Qing Ye; Jing Cai; Xin Yang; Yao Fu; Xiangshan Fan; Hongyan Wu; Jun Chen; Yudong Qiu; Shen Yue
Journal:  Cell Death Dis       Date:  2021-03-11       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.